<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>268255</rcn>
  <id>101189261</id>
  <acronym>ASTEROID</acronym>
  <teaser>The pharmaceutical and medical fields need more predictive models to assess the effects of drugs on patients. The demand arisesfrom the desire to replace animal tests, enhance predictability, and reduce drug development time and costs. In personalizedmedicine, there's a need...</teaser>
  <objective>The pharmaceutical and medical fields need more predictive models to assess the effects of drugs on patients. The demand arises
from the desire to replace animal tests, enhance predictability, and reduce drug development time and costs. In personalized
medicine, there's a need for tools like companion diagnostics to identify patients who will benefit and respond from specific
treatments.
Recent changes in EU and US regulations, allowing drug candidates to be submitted without animal testing, have led to the
development of alternative solutions like 3D cell culture and organs-on-a-chip. These technologies have shown promise in predicting
drug effects on patients, but 3 scientific challenges persist, namely including functional vascular interfaces, multilayer tissue
equivalent reconstruction without PDMS, and cultivating interconnected organs with varying oxygen concentrations. Also, 2
industrial bottlenecks on the compatibility with multiwell plate formats and the need for reproducible biological protocols are
present.
Cherry Biotech has developed a 3D cell culture platform that addresses these bottlenecks with three innovations: the Microfluidic
Perfusion Lid (MPL), the Hydroflat, and the Cubix control unit. These innovations have received approval from industrial and hospital
partners and has been patented in Europe and US.
The company aims to address the preclinical drug development (CubiX RUO, 2026) market and the precision medicine market (CubiX
CDx, 2030). The preclinical drug development market is growing rapidly due to favorable regulatory changes, while the precision
oncology market is driven by biomarker-based assays for guiding medical treatments.
Cherry Biotech's work not only has financial implications but also has a significant impact on human health and animal welfare by
offering predictive models and reducing the need for animal testing. It contributes to technological advancement and innovation in
the EU.</objective>
  <title>Multi-organ toxicity and efficacy test platform for Personalized medicine &amp; Drug development</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>2499831.25</ecMaxContribution>
  <startDate>2024-09-02</startDate>
  <endDate>2027-03-01</endDate>
  <ecSignatureDate>2024-12-08</ecSignatureDate>
  <duration>30</duration>
  <status>SIGNED</status>
  <keywords>Organ on Chips, Microphysiological System, precision oncology, Preclinical Drug Development, Companion, diagnostic</keywords>
  <identifiers>
    <grantDoi>10.3030/101189261</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2024-12-31 09:30:22</sourceUpdateDate>
  <contentCreationDate>2024-12-24 10:19:25</contentCreationDate>
  <contentUpdateDate>2024-12-24 10:19:24</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:48:57</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>455000</rcn>
        <id>455000-new-platform-for-precision-medicine-and-drug-development</id>
        <title>New platform for precision medicine and drug development</title>
        <contentUpdateDate>2025-03-28 08:18:32</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode>/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>56829</rcn>
        <title>HORIZON-EIC-2024-ACCELERATOR-02</title>
        <identifier>HORIZON-EIC-2024-ACCELERATOR-02</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>56829</rcn>
        <title>HORIZON-EIC-2024-ACCELERATOR-02</title>
        <identifier>HORIZON-EIC-2024-ACCELERATOR-02</identifier>
      </call>
      <organization netEcContribution="2499831.25" totalCost="0" source="corda" order="1" ecContribution="2499831.25" terminated="false" sme="true" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>2561058</rcn>
        <id>934242018</id>
        <vatNumber>FR47801463902</vatNumber>
        <legalName>CHERRY BIOTECH</legalName>
        <shortName>CHERRY BIOTECH</shortName>
        <address>
          <street>2EME ETAGE, HALLS A-B ET C14 RUE DE LA BEAUNE</street>
          <city>MONTREUIL</city>
          <postalCode>93100</postalCode>
          <country>FR</country>
          <geolocation>48.11690815,-1.69744898175924</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Seine-Saint-Denis</name>
              <rcn>258740230</rcn>
              <nutsCode>FR106</nutsCode>
              <parents>
                <region>
                  <name>Ile-de-France</name>
                  <rcn>258740264</rcn>
                  <nutsCode>FR10</nutsCode>
                  <parents>
                    <region>
                      <name>Ile-de-France</name>
                      <rcn>258742824</rcn>
                      <nutsCode>FR1</nutsCode>
                      <parents>
                        <region>
                          <name>France</name>
                          <rcn>258902568</rcn>
                          <nutsCode>FR</nutsCode>
                          <euCode>FR</euCode>
                          <isoCode>FR</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>France</name>
              <rcn>258902568</rcn>
              <nutsCode>FR</nutsCode>
              <euCode>FR</euCode>
              <isoCode>FR</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>708772</rcn>
        <id>HORIZON_HORIZON-EIC-2024-ACCELERATOROPEN-01</id>
        <code>HORIZON-EIC-2024-ACCELERATOROPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Accelerator Open 2024</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1357180</rcn>
        <id>101189261_221108_PUBLIHORIZON</id>
        <title>Charting new paths in adipose tissue organoid development via stromal vascular fraction</title>
        <details>
          <authors>Mathilde Cadoux, PhD; Emilie Ouanounou; Ghofrane Ben Messaoud; Hadhemi Mejri; Julius Elliot Nyegaard Grothen, PhD; Thomas Askov Pedersen, PhD; Dario Fassini, PhD.</authors>
          <journalNumber>23</journalNumber>
          <journalTitle>ALTEX Proceeding</journalTitle>
          <publishedPages></publishedPages>
          <publishedYear>2025</publishedYear>
          <publisher>ALTEX edition</publisher>
        </details>
        <identifiers>
          <issn>2194-0479</issn>
        </identifiers>
        <sourceUpdateDate>2025-09-06 01:23:00</sourceUpdateDate>
        <contentUpdateDate>2025-09-08 12:34:31</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode>/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/CONFERENCE_PROCEEDING</code>
              <title>Conference proceedings</title>
              <displayCode>/Conference proceedings</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1357179</rcn>
        <id>101189261_221107_PUBLIHORIZON</id>
        <title>Development of a 3D immunocompetent breast cancer model to accelerate drug testing and personalised medicine</title>
        <details>
          <authors>Priyanka Fernandes, Harry Dawson, Ethan N.P Vong, Pierre Savagner, Dario Fassini</authors>
          <journalNumber>23</journalNumber>
          <journalTitle>ALTEX Proceeding</journalTitle>
          <publishedPages></publishedPages>
          <publishedYear>2025</publishedYear>
          <publisher>ALTEX edition</publisher>
        </details>
        <identifiers>
          <issn>2194-0479</issn>
        </identifiers>
        <sourceUpdateDate>2025-09-06 01:23:00</sourceUpdateDate>
        <contentUpdateDate>2025-09-08 12:34:31</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode>/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/CONFERENCE_PROCEEDING</code>
              <title>Conference proceedings</title>
              <displayCode>/Conference proceedings</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode>/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="40">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-EIC-ACC</code>
        <title>HORIZON EIC Accelerator</title>
        <displayCode>/HORIZON EIC Accelerator</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>